# US 8,431,128 B2 · Enterococcus antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,431,128 B2
- Document ID: US8431128B2
- Status: Granted
- Kind: B2
- Application number: 13/323,084
- Filed: 2011-12-12
- Published: 2012-04-05
- Granted: 2013-04-30
- Earliest claimed: 2003-05-30
- Assignees: Intercell AG
- Applicants: Andreas Meinke; Eszter Nagy; Markus Hanner; Dieter Gelbmann
- Inventors: Andreas Meinke; Eszter Nagy; Markus Hanner; Dieter Gelbmann
- Web page: https://patentgrep.com/patent/US8431128B2

## CPC

- C07K 16/1267: Gram-positive bacteria
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 27/02: Ophthalmic agents
- A61P 31/04: Antibacterial agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- C12Q 1/689: for bacteria
- G01N 33/56916: {Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/53: {DNA (RNA) vaccination}
- C07K 2317/21: from primates, e.g. man
- C12Q 2600/158: Expression markers
- G01N 2500/00: Screening for compounds of potential therapeutic value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.

## Claims

### Claim 1

A purified antibody, or at least an effective part thereof, which binds specifically to at least a selective part of an isolated antigenic fragment of SEQ ID NO:198 consisting of amino acids 4-28, 39-45, 52-58, 69-82, 93-115, 122-128, 135-140, 146-163, 177-192, 209-215, 221-232, 271-284, 331-337, 341-352, 360-378, 383-390, 392-401, 409-422, 428-435, 462-470, 474-480, 482-496, 531-539, 541-549, 551-560, 562-569, 576-582, 598-618, 98-127, 98-123 or 104-126 of SEQ ID NO: 198.

### Claim 2 (depends on 1)

The purified antibody or effective part thereof of claim 1, which binds specifically to at least a selective part of an isolated antigenic fragment consisting of the amino acid sequence of amino acids 98-127, 98-123 or 104-126 of SEQ ID NO: 198.

### Claim 3 (depends on 1)

A hybridoma cell line which produces the antibody according to claim 1.

### Claim 4 (depends on 1)

A method of treating or preventing an infection with Enterococcus faecalis comprising administering to an individual in need thereof the antibody according to claim 1 in an effective amount.

### Claim 5 (depends on 1)

The antibody according to claim 1
a) wherein the antibody is a monoclonal antibody;
b) wherein the antibody is a humanized antibody;
c) wherein the antibody is a chimeric antibody; and/or
d) wherein said effective part comprises an Fab fragment.

### Claim 6 (depends on 1)

A composition comprising an antibody according to claim 1, optionally containing a pharmaceutically acceptable carrier or excipient.

### Claim 7 (depends on 1)

A method for producing an antibody as defined in claim 1, characterized by the following steps:
a) initiating an immune response in a non-human animal by administering an isolated hyperimmune serum-reactive antigen fragment as defined in claim 1, to said animal;
b) removing an antibody-containing body fluid from said animal; and
c) producing the antibody by subjecting said antibody-containing body fluid to further purification steps.

### Claim 8 (depends on 1)

A method for producing an antibody as defined in claim 1, characterized by the following steps:
a) initiating an immune response in a non-human animal by administering an isolated hyperimmune serum-reactive antigen fragment as defined in claim 1, to said animal;
b) removing the spleen or spleen cells from said animal;
c) producing hybridoma cells of said spleen or spleen cells;
d) selecting and cloning hybridoma cells specific for said antigen fragment;
e) producing the antibody by cultivation of said cloned hybridoma cells; and
f) optionally conducting further purification steps.